Clinical Trials on Prostate Cancers

Total 52827 results

University of Southern California
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Terminated

Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Amgen

Completed

AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

Cancer | Prostate Cancer | Castrate-Resistant Prostate Cancer | Mestastatic Prostate Cancer
ORIC Pharmaceuticals

Recruiting

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Metastatic Prostate Cancer | Neuroendocrine Prostate Cancer

United States
Roswell Park Cancer Institute
Merck Sharp & Dohme LLC

Terminated

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Barbara Ann Karmanos Cancer Institute

Completed

Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of California, Irvine
Bristol-Myers Squibb

Completed

Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Hormone-refractory Prostate Cancer

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Hormone-refractory Prostate Cancer

United States
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC

Prostate Cancer Castration-resistant Prostate Cancer

China
National Cancer Institute (NCI)

Terminated

Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Withdrawn

High-Intensity Focused Ultrasound in Treating Participants With Intermediate and High-risk Prostate Cancer

Prostate Cancer Stage I AJCC V6 | Prostate Cancer Stage II | Prostate Cancer Stage III

United States
Arno Therapeutics

Unknown

Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Metastatic Prostate Cancer | Androgen-independent Prostate Cancer

United Kingdom
University of Washington
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer

Stage II Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate

United States
John P. Fruehauf
Sanofi

Withdrawn

Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate (2007-5904)

Prostate Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Adenocarcinoma of the Prostate
National Cancer Institute (NCI)

Completed

Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Tivantinib in Treating Patients With Metastatic Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer

Prostate Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Adenocarcinoma of the Prostate

United States
National Cancer Institute (NCI)

Completed

Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate

Stage I Prostate Cancer | Stage II Prostate Cancer | Adenocarcinoma of the Prostate

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer (ASPIRE-PCa)

Prostate Cancer | Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

Spain, Taiwan, France, Algeria, Argentina, Australia, Austria, Brazil, Canada, Colombia, Egypt, Germany, Indonesia, Israel, Italy, Korea, Republic of, Lebanon, Mexico, Netherlands, New Zealand, Oman, Peru, Philippines, Saudi Arabia, Sin... and more
Providence Health & Services
MedImmune LLC

Completed

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Cancer of the Prostate

United States
Cliniques universitaires Saint-Luc- Université...
Sanofi

Completed

Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer

Metastatic Prostate Cancer | Hormone Resistant Prostate Cancer

Belgium, Luxembourg
University of Chicago
National Cancer Institute (NCI)

Completed

Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Terminated

Saracatinib in Treating Patients With Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Mayo Clinic

Completed

Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer

Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of Washington
National Cancer Institute (NCI); AstraZeneca

Terminated

Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer

Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Prostate Adenocarcinoma Without Neuroendocrine Differentiation

United States
Tianjin Medical University Second Hospital

Recruiting

Selective Treatment According to Molecular Subtype of Prostate Cancer (STAMP)

Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

China
University of Southern California
National Cancer Institute (NCI); AEterna Zentaris

Completed

Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Stage IV Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Unknown

Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage IV Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Institute of Cancer Research, United Kingdom
Prostate Cancer UK

Recruiting

Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) - MAESTRO (MAESTRO)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

United Kingdom
Astellas Pharma Global Development, Inc.
Pfizer

Completed

Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) (TRUMPET)

Prostate Cancer | Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

United States
University of Washington
National Cancer Institute (NCI)

Withdrawn

Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage IV Prostate Cancer

United States
Jonsson Comprehensive Cancer Center

Completed

68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery

Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v7 | Stage III Prostate Cancer AJCC v7 | Stage IIB Prostate Cancer AJCC v7

United States
National Cancer Institute (NCI)

Completed

BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Recurrent Prostate Cancer | Bone Metastases | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Hormone-Resistant Prostate Cancer

United States
Ryan Kohlbrenner, MD
Radiological Society of North America

Completed

Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion

Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...

United States
Bellicum Pharmaceuticals

Suspended

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Spanish Oncology Genito-Urinary Group
Pivotal S.L.

Active, not recruiting

Radiation-hormone and Docetaxel VS Radiation-hormone in Patients With High-Risk Localized Prostate Cancer (QRT-SOGUG)

Prostate Cancer Stage III | Prostate Cancer Stage IV
NorthShore University HealthSystem
National Cancer Institute (NCI); Wake Forest University Health Sciences; Van... and other collaborators

Completed

Clinical Validity and Utility of Genomic-targeted Chemoprevention of PCa: Aim 4a

Prostate Cancer | Prostate Cancer, Familial | Hereditary Prostate Cancer
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Robotic Athermal Nerve-Sparing Radical Prostatectomy

Stage I Prostate Cancer | Stage IIA Prostate Cancer
Jonsson Comprehensive Cancer Center

Withdrawn

Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer

Prostate Adenocarcinoma | Stage II Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
National Cancer Institute (NCI)

Enrolling by invitation

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Cancer Of Prostate | Prostate Neoplasms | Prostatic Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer

Stage III Prostate Cancer | Stage IV Prostate Cancer

United States
University of Oxford
Vaccitech (UK) Limited

Unknown

VAccination in Early and ADvanced Prostate caNCEr (ADVANCE)

Castration-resistant Prostate Cancer | Intermediate Risk Prostate Cancer

United Kingdom

Clinical Trials on Prostate Cancers

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations